Abstract

Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer

Butt Sabeeh-Ur-Rehman and Shah Bhaumik

Immune checkpoint inhibitors include programmed cell death-1 receptor inhibitors (PD-1), programmed cell death ligand-1 inhibitors and CTLA-4 inhibitors and are novel treatment against certain cancers like non-small cell lung cancer (NSCLC), melanoma and renal cell cancer. They act by boosting the immune response against cancer cells and have improved the prognosis of patients with these cancers significantly shifting the treatment paradigm.